Literature DB >> 8392011

Human glucagon-like peptide-1 receptor gene. Localization to chromosome band 6p21 by fluorescence in situ hybridization and linkage of a highly polymorphic simple tandem repeat DNA polymorphism to other markers on chromosome 6.

M Stoffel1, R Espinosa, M M Le Beau, G I Bell.   

Abstract

Glucagon-like peptide-1 is a fragment of proglucagon secreted by intestinal L-cells. It has potent glucose-dependent insulin secretory effects and also suppresses gastric acid secretion in the stomach. The biological actions of GLP-1 are mediated by the GLP-1 receptor, the structure of which has recently been determined. Defects in insulin secretion are a common feature of NIDDM and as such the GLP-1 receptor is a candidate for contributing to the development of this clinically and genetically heterogeneous disorder. As a first step in determining the role of the GLP-1 receptor in the development of NIDDM, we have isolated the human GLP-1 receptor gene and mapped it to chromosome 6, band p21.1, using the technique of fluorescence in situ hybridization. We also identified a simple tandem repeat DNA polymorphism in the human GLP-1 receptor gene of the form (TG)n. This DNA polymorphism has 14 alleles and a heterozygosity of > 0.8. We have used this DNA polymorphism to localize the GLP-1 receptor gene within the genetic map of the short arm of chromosome 6. This DNA polymorphism will facilitate genetic studies of the contribution of the GLP-1 receptor gene to impaired beta-cell function and NIDDM.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392011     DOI: 10.2337/diab.42.8.1215

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  19 in total

Review 1.  Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?

Authors:  Lin Li
Journal:  Neurosci Bull       Date:  2007-01       Impact factor: 5.203

2.  Absence of linkage of phonological coding dyslexia to chromosome 6p23-p21.3 in a large family data set.

Authors:  L L Field; B J Kaplan
Journal:  Am J Hum Genet       Date:  1998-11       Impact factor: 11.025

Review 3.  Glucagon-like peptide 1 (GLP-1) and metabolic diseases.

Authors:  C M Rotella; L Pala; E Mannucci
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

Review 4.  Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists.

Authors:  Josh Reed; Venkateswarlu Kanamarlapudi; Stephen Bain
Journal:  Cardiovasc Endocrinol Metab       Date:  2018-02-14

5.  Candidate gene studies in pedigrees with maturity-onset diabetes of the young not linked with glucokinase.

Authors:  Y Zhang; M Warren-Perry; P J Saker; A T Hattersley; A D Mackie; J D Baird; R H Greenwood; M Stoffel; G I Bell; R C Turner
Journal:  Diabetologia       Date:  1995-09       Impact factor: 10.122

Review 6.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

7.  GLP-1R activation for the treatment of stroke: updating and future perspectives.

Authors:  Vladimer Darsalia; David Nathanson; Thomas Nyström; Thomas Klein; Åke Sjöholm; Cesare Patrone
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

8.  Localization of a (CA)n repeat in glucagon-like peptide-1 receptor gene (Glp1r) to proximal mouse chromosome 17 and its linkage to other markers.

Authors:  E E Kershaw; S C Chua; R L Leibel
Journal:  Mamm Genome       Date:  1995-04       Impact factor: 2.957

Review 9.  Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?

Authors:  Guojing Luo; Hong Liu; Hongyun Lu
Journal:  Br J Clin Pharmacol       Date:  2016-01       Impact factor: 4.335

Review 10.  Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

Authors:  David J Grieve; Roslyn S Cassidy; Brian D Green
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.